Your browser doesn't support javascript.
Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England.
Wells, Philippa M; Doores, Katie J; Couvreur, Simon; Nunez, Rocio Martinez; Seow, Jeffrey; Graham, Carl; Acors, Sam; Kouphou, Neophytos; Neil, Stuart J D; Tedder, Richard S; Matos, Pedro M; Poulton, Kate; Lista, Maria Jose; Dickenson, Ruth E; Sertkaya, Helin; Maguire, Thomas J A; Scourfield, Edward J; Bowyer, Ruth C E; Hart, Deborah; O'Byrne, Aoife; Steel, Kathryn J A; Hemmings, Oliver; Rosadas, Carolina; McClure, Myra O; Capedevilla-Pujol, Joan; Wolf, Jonathan; Ourselin, Sebastien; Brown, Matthew A; Malim, Michael H; Spector, Tim; Steves, Claire J.
  • Wells PM; Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK.
  • Doores KJ; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Couvreur S; Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK.
  • Nunez RM; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Seow J; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Graham C; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Acors S; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Kouphou N; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Neil SJD; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Tedder RS; Department of Infectious Disease, Imperial College London, UK.
  • Matos PM; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Poulton K; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Lista MJ; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Dickenson RE; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Sertkaya H; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Maguire TJA; Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Scourfield EJ; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Bowyer RCE; Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK.
  • Hart D; Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK.
  • O'Byrne A; Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Steel KJA; Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Hemmings O; Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Rosadas C; Department of Infectious Disease, Imperial College London, UK.
  • McClure MO; Department of Infectious Disease, Imperial College London, UK.
  • Capedevilla-Pujol J; Zoe Global Ltd., Westminster Bridge Rd, London, UK.
  • Wolf J; Zoe Global Ltd., Westminster Bridge Rd, London, UK.
  • Ourselin S; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
  • Brown MA; Department of Medical & Molecular Genetics, Guy's and St Thomas' Hospital NHS Trust and King's College London NIHR Biomedical Research Centre, London, UK.
  • Malim MH; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Spector T; Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK.
  • Steves CJ; Department of Twin Research, King's College London, St Thomas' Hospital, London SE1 7EH, UK. Electronic address: Claire.J.Steves@kcl.ac.uk.
J Infect ; 81(6): 931-936, 2020 12.
Article in English | MEDLINE | ID: covidwho-866901
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms.

METHODS:

We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million.

FINDINGS:

We demonstrated a seroprevalence of 12% (51 participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive.

INTERPRETATION:

Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response.

FUNDING:

NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Asymptomatic Infections / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: J Infect Year: 2020 Document Type: Article Affiliation country: J.jinf.2020.10.011

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Asymptomatic Infections / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: J Infect Year: 2020 Document Type: Article Affiliation country: J.jinf.2020.10.011